



(12) Translation of
European patent specification

(11) NO/EP 2976331 B1

NORWAY

(19) NO
(51) Int Cl.
C07D 233/72 (2006.01)
C07K 5/00 (2006.01)
C07K 14/00 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2017.07.10
(80)	Date of The European Patent Office Publication of the Granted Patent	2017.03.01
(86)	European Application Nr.	14710915.1
(86)	European Filing Date	2014.03.19
(87)	The European Application's Publication Date	2016.01.27
(30)	Priority	2013.03.21, EP, 13160384
(84)	Designated Contracting States:	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
(73)	Proprietor	Sanofi-Aventis Deutschland GmbH, Brüningstraße 50, 65929 Frankfurt am Main, DE-Tyskland
(72)	Inventor	HENKEL, Bernd, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, DE-Tyskland
(74)	Agent or Attorney	Tandbergs Patentkontor AS, Postboks 1570 Vika, 0118 OSLO, Norge

(54) Title **SYNTHESIS OF HYDANTOIN CONTAINING PEPTIDE PRODUCTS**

(56) References
Cited:

QUIBELL M ET AL: "SYNTHESIS OF AZAPEPTIDES BY THE FMOC/TERT-BUTYL/POLYAMIDE TECHNIQUE", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1, CHEMICAL SOCIETY, LETCHWORTH; GB, no. 22, 21 November 1993 (1993-11-21), pages 2843-2849, XP001109158, ISSN: 0300-922X, DOI: 10.1039/P19930002843

ROYO M ET AL: "Solid-phase syntheses of constrained RGD scaffolds and their binding to the alphavbeta3 integrin receptor", TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 42, no. 42, 15 October 2001 (2001-10-15), pages 7387-7391, XP004306055, ISSN: 0040-4039, DOI: 10.1016/S0040-4039(01)01510-6

EWA WITKOWSKA ET AL: "New analogues of laminin active fragment YIGSR: synthesis and biological activity in vitro and in vivo", JOURNAL OF PEPTIDE SCIENCE, vol. 10, no. 5, 26 April 2004 (2004-04-26), pages 285-290, XP055067534, ISSN: 1075-2617, DOI: 10.1002/psc.537

REDA MHIDIA ET AL: "Selective cleavage of an azaGly peptide bond by copper(II). Long-range effect of histidine residue", JOURNAL OF PEPTIDE SCIENCE, vol. 16, 1 January 2010 (2010-01-01), pages 141-147, XP055067533, ISSN: 1075-2617, DOI: 10.1002/psc.1211

YAHALOM D ET AL: "Structure-activity studies of reduced-size gonadotropin-releasing hormone agonists derived from the sequence of an endothelin antagonist", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 43, no. 15, 27 July 2000 (2000-07-27), pages 2824-2830, XP002514536, ISSN: 0022-2623, DOI: 10.1021/JM9904432O

G BHALAY ET AL: "Multiple solid-phase synthesis of hydantoins and thiohydantoins", MOLECULAR DIVERSITY, vol. 3, no. 3, 1 January 1998 (1998-01-01), pages 195-198, XP055067457,

CHONG P Y ET AL: "Solid Phase Hydantoin Synthesis: An Efficient and Direct Conversion of Fmoc-Protected Dipeptides to Hydantoins", TETRAHEDRON LETTERS, ELSEVIER,

AMSTERDAM, NL, vol. 40, no. 13, 26 March 1999 (1999-03-26), pages 2493-2496, XP004158068, ISSN: 0040-4039, DOI: 10.1016/S0040-4039(99)00243-9 cited in the application

J VAZQUEZ ET AL: "Re-Evaluation of a Solid-Phase Hydantoin Synthesis", LETTERS IN ORGANIC CHEMIS, vol. 1, 1 January 2004 (2004-01-01), pages 224-226, XP055067432, XIAO-YI XIAO ET AL: "Selective Solid Phase Synthesis of Ureas and Hydantoins from Common Phenyl Carbamate Intermediates", JOURNAL OF ORGANIC CHEMISTRY, ACS, US, vol. 62, 3 October 1997 (1997-10-03), pages 6968-6973, XP002105235, ISSN: 0022-3263, DOI: 10.1021/JO971087I

ALBERICIO F ET AL: "MILD, ORTHOGONAL SOLID-PHASE PEPTIDE SYNTHESIS: USE OF N-ALPHA-DITHIASUCCINOYL (DTS) AMINO ACIDS AND N-(ISO-PROPYLDITHIO)CARBONYLPROLINE, TOGETHER WITH P-ALKOXYBENZYL ESTER ANCHORING LINKAGES", INTERNATIONAL JOURNAL OF PEPTIDE AND PROTEIN RESEARCH, MUNKSGAARD, COPENHAGEN, DK, vol. 30, 1 January 1987 (1987-01-01), pages 177-205, XP009014228, ISSN: 0367-8377


MANUELA MEUSEL & MICHAEL GUETSCHOW: "RECENT DEVELOPMENTS IN HYDANTOIN CHEMISTRY. A REVIEW", ORGANIC PREPARATIONS AND PROCEDURES INTERNATIONAL, ORGANIC PREPARATION AND PROCEDURES CO., NEWTON HIGHLANDS, MA, US, vol. 36, no. 5, 1 January 2004 (2004-01-01), pages 391-443, XP009170513, ISSN: 0030-4948, DOI: 10.1080/00304940409356627 [retrieved on 2009-02-18]

Anonymous: "Lixisenatide - Wikipedia, the free encyclopedia", , 24 February 2013 (2013-02-24), pages 1-4, XP055120784, Retrieved from the Internet: URL:<http://en.wikipedia.org/w/index.php?title=Lixisenatide&oldid=540119995> [retrieved on 2014-05-28]

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. En fremgangsmåte for syntetisering av et peptidprodukt omfattende en N-terminal
5 hydantoingruppe med formel (I) eller et salt eller solvat derav:




10 hvor

R_1 og R_2 er aminosyre-sidekjeder,

P er en peptid-rest, og

(*) i hvert tilfelle uavhengig av hverandre betyr et eventuelt asymmetrisk C-atom,
omfattende de følgende trinn:

15 (a) kobling av en hydantoin-byggeblokk med formel (II)



20 hvor

R_1' er en eventuelt beskyttet aminosyre-sidekjede,

R_2' er en eventuelt beskyttet aminosyre-sidekjede,

Z er en karboksygruppe, og

25 (*) i hvert tilfelle uavhengig av hverandre betyr et eventuelt asymmetrisk C-atom til et peptidprodukt med formel (III)




30 hvor


P' er en peptid-rest som eventuelt omfatter beskyttede aminosyre-sidekjeder,
fortrinnsvis bundet til en fastfasebærer,

- (b) eventuelt avspalting av beskyttende grupper fra beskyttede aminosyre-sidekjeder, og
 (c) isolering og eventuelt rensing av peptidproduktet (I).

- 5 **2.** Fremgangsmåte ifølge krav 1, hvor R_1 og/eller R_2 er aminosyre-sidekjeder beskyttet med en syre-labil beskyttende gruppe, en base-labil beskyttende gruppe eller en annen beskyttende gruppe.
- 10 **3.** Fremgangsmåte ifølge krav 1, hvor R_1 og/eller R_2 er beskyttet Glu-, Gin-, Asp-, Asn- eller Ser-sidekjeder.
- 15 **4.** Et peptidprodukt omfattende des[1-12]-hydantoin-(15-44)-AVE0010, hvor des[1-12]-hydantoin-(15-44)-AVE0010 har aminosyresekvensen X-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Ser-Lys-Lys-Lys-Lys-Lys-Lys-NH₂, hvor X koblet til aminosyresekvensen er:



- 20 **5.** Anvendelse av en forbindelse med formel (II) eller et salt eller solvat derav, som en byggeblokk for syntese av peptider, særlig ved fremstilling av et referansemateriale for kvalitetskontroll av peptidprodukter,



25
 hvor

- 30 R_1 er en eventuelt beskyttet aminosyre-sidekjede valgt fra gruppen His, Arg, Cys, Asp, Gin, Lys, Met, Asn, Ser, Tyr, Trp og unaturlige aminosyrer, fortrinnsvis unaturlige aminosyrer med et heteroatom i sidekjeden,

R_2 er en eventuelt beskyttet aminosyre-sidekjede valgt fra gruppen His, Arg, Cys, Asp, Gin, Lys, Met, Asn, Ser, Tyr, Trp og unaturlige aminosyrer, fortrinnsvis unaturlige aminosyrer med et heteroatom i sidekjeden,

Z er en karboksygruppe, og

5 (*) i hvert tilfelle uavhengig av hverandre betyr et eventuelt asymmetrisk C-atom.